MAZE (MAZE) Stock Price & Analysis
MAZE (MAZE) rose 0.61% to USD 26.37 as of September 9, 2026 at 10:11 UTC, according to Nexqual real-time market data.
MAZE last closed at USD 26.37; the session ranged USD 25.3–26.57 on volume of 365,001 shares. Market capitalization is —, with a 52-week range of USD 15.7–53.65 (NGM). Source: Nexqual, September 9, 2026 at 10:11 UTC.
Key Statistics (as of September 9, 2026 at 10:11 UTC)
| Price | USD 26.37 |
|---|---|
| Change | ▲ 0.61% (up) |
| Previous Close | USD 26.37 |
| Open | USD 26.37 |
| Day Range | USD 25.3 – 26.57 |
| 52-Week Range | USD 15.7 – 53.65 |
| Volume | 365,001 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (MAZE)
Nexqual's technical model rates MAZE "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.94 (neutral) |
| vs SMA50 | Below (USD 28.59) |
| MACD | -0.5 (negative) |
From MAZE's Latest SEC 10-K Filing (filed 2026-03-25)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | USD 46.09 | ▼ 3.27% |
| MBX | MBX Biosciences, Inc. | USD 62.99 | ▲ 2.56% |
| SION | Sionna Therapeutics, Inc. | USD 7.3 | ▲ 8.15% |
| BCAX | Bicara Therapeutics Inc. | USD 23.71 | ▲ 1.59% |
| MLYS | Mineralys Therapeutics, Inc. | USD 31.12 | ▲ 10.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:11 UTC. This page is informational and not investment advice.